The global market for Primary Sclerosing Cholangitis (PSC) is expected to be worth US$ 151.07 million in 2023. Because of rising alcohol consumption, the overall demand for Primary Sclerosing Cholangitis (PSC) is expected to grow at a CAGR of 7.6% between 2023 and 2033, totaling around US$ 314.26 Million by 2033. The Primary Sclerosing Cholangitis …
Category Archives: Healthcare Trends
Hyperglycemia Treatment Market to grow at a 12.3% CAGR from 2023 to 2033, Insulin Therapy to be Most Common Treatment Approach: FMI Report
According to Future Market Insights, the global hyperglycemia treatment is expected to grow at a CAGR of 12.3% between 2023 and 2033, reaching US$ 1,596 Million in 2033. With the growing number of young people prone to stress levels and poor eating habits, hyperglycemia treatments have become more popular. According to a new study, COVID-19 …
Hyperammonemia Treatment Market to reach US$ 2,100 Million by 2033, glycerol phenylbutyrate to account for over 1/3rd of all Treatments: FMI
According to a recently published study by Future Market Insights, the global hyperammonemia treatment market size is expected to reach a valuation of US$ 1,318.05 Million in 2023 and is projected to reach US$ 2,100 Million by 2033, trailing a CAGR of 4.77%. The rising prevalence of urea cycle disorders and extensive research and development …
Research and Development for Hutchinson Gilford progeria syndrome (HGPS) Therapeutics to Register 8.5% CAGR: FMI Study
During the forecast period 2023-2033, the Hutchinson Gilford progeria syndrome (HGPS) Therapeutics market is expected to grow at a value of 8.5% CAGR, according to Future Market Insights. By the year 2033, the global market for Hutchinson Gilford progeria syndrome is expected to rise up to a market valuation of US$ 15,990 Million. Around 400 …
Intestinal Fistula Treatment Market Value to reach US$ 46.82 Billion by 2033; Proton-Pump Inhibitor Drugs to account for 45% of all Treatments: FMI Report
The global intestinal fistula treatment market is expected to be valued at US$ 26.64 Billion in 2023. With the continuous improvements in drugs and biotechnology, the overall demand for intestinal fistula treatment is projected to grow at a CAGR of 5.8% between 2023 and 2033, totaling around US$ 46.82 Billion by 2033. Factors such as …
Increasing Prevalence of Hormonal Problems to Propel the Growth in the Market for Hypopituitarism Diagnostics at 6% CAGR: FMI Study
The global Hypopituitarism Diagnostics Market is expected to garner a market value of US$ 250 Million in 2023 and is expected to accumulate a market value of US$ 447.41 Million by registering a CAGR of 6% in the forecast period 2023-2033. The market for Hypopituitarism Diagnostics registered a CAGR of 4% in the historical period …
Takotsubo Syndrome Therapeutics Market to reach US$ 2.85 Billion by 2033; growing at a CAGR of 6.1%: FMI Report
The global takotsubo syndrome therapeutics market is predicted to exceed an impressive valuation of US$ 2.85 Billion in 2033, with a compound annual growth rate (CAGR) of 6.1% estimated from 2023 to 2033. In both industrialized and developing economies, cardiovascular diseases are the leading cause of death. The rising prevalence of cardiovascular problems such as …
Rising Focus of Government Organizations to Propel the Growth in the Market for Congenital Hyperinsulinism Treatment at 6% CAGR: FMI Study
The global Congenital Hyperinsulinism Treatment Market is expected to garner a market value of US$ 100 Million in 2023 and is expected to accumulate a market value of US$ 179.08 Million by registering a CAGR of6% in the forecast period 2023-2033. The market for Congenital Hyperinsulinism registered a CAGR of 4% in the historical period …
Andersen Tawil Syndrome Treatment Market to reach US$ 4.2 Billion by 2033; Type-1 Treatment to comprise 59% of all Procedures: FMI Report
As per a recently published study by Future Market Insights, the global Andersen Tawil syndrome treatment market is expected to surpass an impressive valuation of US$ 1.9 Billion in 2023 and is projected to reach US$ 4.2 Billion by 2033, with a CAGR of 8.26%. Rising government assistance, provision of incentives to pharmaceutical companies, increasing …
PCSK9 Inhibitors Sales to expand at a 15.8% CAGR from 2023 to 2033, Repatha-based Inhibitors to be Most Widely Used: FMI Report
A recently published study by FMI expects the global PCSK9 inhibitors market to augment at a 15.8% CAGR from 2022 to 2032. By the end of the said assessment period, a valuation of US$ 13 Billion is expected for the market. Monoclonal antibodies are a kind of biologic medicine that inhibits PCSK9. PCSK9 inhibitors bind …